Suppr超能文献

双膦酸盐类药物的最新进展以及双膦酸盐类药物所致颌骨坏死的潜在病理生物学机制

Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis.

作者信息

Sarin J, DeRossi S S, Akintoye S O

机构信息

Department of Oral Medicine, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Oral Dis. 2008 Apr;14(3):277-85. doi: 10.1111/j.1601-0825.2007.01381.x.

Abstract

Osteonecrosis of the jaws is a major complication associated with long-term use of bisphosphonates. While osteonecrosis can arise from other precipitating conditions, bisphosphonate-induced jaw osteonecrosis (BJON) is highly associated with long-term administration of pamidronate (Aredia) and zoledronic acid (Zometa), which are two intravenous bisphosphonate formulations. The underlying pathogenesis of BJON and its site-specific presentation still remain to be fully elucidated. This review will discuss clinically available bisphosphonates, current opinions, pathogenesis, and management guidelines for bisphosphonate-induced jaw osteonecrosis.

摘要

颌骨骨坏死是长期使用双膦酸盐类药物相关的一种主要并发症。虽然骨坏死可由其他诱发情况引起,但双膦酸盐类药物所致颌骨骨坏死(BJON)与长期使用帕米膦酸二钠(阿可达)和唑来膦酸(择泰)密切相关,这两种药物均为静脉用双膦酸盐制剂。BJON的潜在发病机制及其部位特异性表现仍有待充分阐明。本综述将讨论临床上可用的双膦酸盐类药物、当前观点、发病机制以及双膦酸盐类药物所致颌骨骨坏死的管理指南。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验